Colchicine is one of the cornerstones of treatment for gout, but emerging research is showing new therapeutic uses beyond that condition. Learn more about these potential novel uses of an established drug.
Colchicine – an established medication with new purpose
Printable Q&A for Offline SubmissionQuiz-summary
0 of 15 questions completed
Questions:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Information
You have already completed the module before. Hence you can not start it again.
Module is loading…
You have to finish following quiz, to start this quiz:
Results
Results
Time has elapsed
Categories
- Not categorized 0%
-
Thank you, we will review your submission and notify you of your results via email.
If not received within 5 hours due to spam, don’t worry, it will show in your profile.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- Answered
- Review
- Question 1 of 15
1. Question
1. Colchicine is currently approved for the prevention and treatment of:
- Question 2 of 15
2. Question
2. Which statement is incorrect?
- Question 3 of 15
3. Question
3. Which of the listed anti-inflammatory effects are true of the mechanism of action of colchicine?
- Question 4 of 15
4. Question
4. The replication of viruses that depend on the microtubule network for intracellular transport of viral particles in the host cell can be inhibited by tubulin ligands:
- Question 5 of 15
5. Question
5. Which statement is incorrect?
- Question 6 of 15
6. Question
6. Tophaceous gout usually develops over time in the absence of ULT, approximately ___ years after the initial gout flare:
- Question 7 of 15
7. Question
7. Which statement is incorrect? Atypical gout:
- Question 8 of 15
8. Question
8. For the management of gout flares, the ACR recommends as first-line therapy:
- Question 9 of 15
9. Question
9. ACR recommendations for initiating ULT include:
- Question 10 of 15
10. Question
10. Which statement is correct?
- Question 11 of 15
11. Question
11. For first-line ULT, including those patients with moderate-to-severe CKD, the ACR strongly recommends:
- Question 12 of 15
12. Question
12. Colchicine is efficacious and safe for prevention of recurrent pericarditis, with significant reductions in the risk of recurrence, the risk of rehospitalisation due to pericarditis, as well as the number of patients with persistent symptoms after 72 hours:
- Question 13 of 15
13. Question
13. From the COLCOT, in patients treated with colchicine within 30 days post-MI, a significantly lower risk of ischaemic cardiovascular events as compared to placebo was predominantly due to a lower incidence of:
- Question 14 of 15
14. Question
14. Which statement is incorrect?
- Question 15 of 15
15. Question
15. Colchicine is metabolised in the liver and intestine and is a CYP3A4 and P-gp substrate:
Do you like this? Share with a colleague
[DISPLAY_ULTIMATE_SOCIAL_ICONS]